



DISA Limited
(Company Registration No. 197501110N)
(Incorporated in the Republic of Singapore)

NEWS RELEASE:

DISA DIGITAL SAFETY PTE. LTD. SIGNED PROOF OF CONCEPT AGREEMENTS WITH PRIVATE HEALTHCARE SERVICE PROVIDERS TO TEST ITS AUTOMATED ANTIGEN RAPID TEST (“ART”) MACHINE

SINGAPORE – January 20, 2022 — Disa Digital Safety Pte. Ltd. has signed proof of concept agreements, through its 40% owned associate company, Digital Life Line Pte. Ltd. (“DLL”), with two large Singapore based private healthcare service providers to test the scalability of its patent pending Automated Antigen Rapid Test (“ART”) System (“Automated Machine”) in February 2022.

The Automated Machine requires users to self-register by scanning their NRIC or passport at the kiosk. Users are then required to scan the unique QR code on the ART kit on the Automated Machine to uniquely tag the ART kit to the user for track and trace purposes.

Users will perform the test in front of the Automated Machine in accordance to the test steps as illustrated on the screen of the Automated Machine. Users can then insert the ART cassette into the Automated Machine and leave without having to wait for the test result. The entire process is video recorded and takes no more than 5 minutes for each user. The Automated Machine will take a photo of the ART cassette and the results are sent automatically and digitally to the rightful owners within 15 to 20 minutes after the test is completed.

Each Automated Machine can handle about 10 to 15 tests per hour, operating for 24 hours a day. With the use of the Automated Machine, ART tests can be processed faster. Video recording guarantees the authenticity of the tests. Most importantly, all the ART test results cannot be tampered with as the ART cassette will have to be inserted into the Automated Machine before the result appears.

The Automated Machine hastens the entire ART process which enables service providers to provide more tests within a shorter period. The automation will also enable our partners to overcome the shortage of manpower. The digitalisation will also help to cope with the increasing ART tests volume in view of the fast spreading Omicron variant.

The Automated Machine can be deployed at dormitories, MICE, airports, train stations, hotels, schools, stadiums etc.

“We are pleased to test our technology in Singapore. Through partnerships with the healthcare service providers, we hope to expand this automation system regionally. The automated system can be used for any type of lateral flow point of care and not limited to only COVID-19”, said Mr Eddie Chng, the Managing Director and CEO of DLL.

DLL has licensed the saliva-based ART kit IP from Duke-NUS Medical School and SingHealth. The kit, known as Parallel Amplified Saliva rapid POint-of-caRe Test (PASPORT), uses nanoparticles to bind the virus and uniquely. It also adds as a second type of nanoparticle that binds the first set of nanoparticles to amplify the signal. This makes testing using PASPORT



more sensitive at finding and flagging the virus and allows it to be used at any time of the day, where the sensitivity of the test is not compromised even after eating or drinking. Compared to other ART, amplification enables PASPORT to be extremely sensitive. In a clinical study involving over 100 participants conducted at SGH, PASPORT's sensitivity in detecting the virus was 97% and its specificity at 90.6%, compared to the gold standard PCR test. The invention was reviewed and published by *Microchimica Acta** in November 2021.



**Microchimica Acta*, established in 1937 by Fritz Pregl, is a monthly peer-reviewed scientific journal published by Springer Nature.

About Digital Life Line Pte. Ltd.

DLL, a 40% owned associate company of Disa Digital Safety Pte. Ltd., is a Singapore-based company that deals with the manufacturing and distribution of saliva-based Antigen Rapid Test (ART) kits. DLL has signed tri-party licensing agreement with National University of Singapore (“NUS”) and Singapore Health Services Pte. Ltd. (“SingHealth”) on 8 December 2021 for the use of their new saliva-based COVID-19 ART technology. This technology was co-developed by SingHealth Duke-NUS Academic Medical Centre and the NUS.

About DiSa Digital Safety Pte. Ltd.

DiSa, a wholly-owned subsidiary of DISA Limited, is a Singapore-based technology solution provider that specializes in research and development of cutting-edge digital security solution (“DiSa Asset Protection System”). With its single scan technology and seamless integration, DiSa has been able to provide item level tracking and data with no disruption to the sales process. This technology is now protecting products and categories previously unachievable with traditional serialization methods, saving millions of dollars in prevented returns.

DiSa entered the US market in 2014 launching its Smart Solutions within the largest retailer in the world with a limited store test. After rigorous testing by the Loss Prevention Research Council, USA, DiSa rolled out its Smart Solutions nationwide in 2017.

About DISA Limited

DISA Limited (SGX: 532), is a publicly-traded company on the Singapore Catalist Stock Exchange. More information is available at <http://www.digital-safety.com>.

This announcement has been reviewed by the Company's sponsor, SAC Capital Private Limited (“Sponsor”). This announcement has not been examined or approved by the Singapore Exchange Securities Trading Limited (“SGX-ST”) and the SGX-ST assumes no responsibility for the contents of this announcement including the correctness of any of the statements or opinions made or reports contained in this announcement.

*The contact person for the Sponsor is Mr. Ong Hwee Li (Registered Professional, SAC Capital Private Limited)
Address: 1 Robinson Road, #21-00 AIA Tower, Singapore 048542.
Telephone number: +65 6232 3210*